Monoamine neurotransmitter function and spontaneous recurrence of methamphetamine psychosis

Annals of the New York Academy of Sciences

Volumn 801, Issue , 1996, Pages 415-429

  Yui, Kunio ^a,b   Goto, Kimihiko ^b   Ikemoto, Shigenori ^b   Ishiguro, Takeo ^b  

^a Ministry of Justice   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; METHAMPHETAMINE; MONOAMINE; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN;

ADULT; ANXIETY; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; NORADRENALIN BLOOD LEVEL; PARANOIA; PSYCHOSIS; RECURRENT DISEASE; SENSITIZATION; SEROTONIN BLOOD LEVEL; STRESS;

EID: 0030445969     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb17464.x     Document Type: Conference Paper

References (39)

1. JANOWSKY, D. S. & C. RISCH. 1979. Amphetamine psychosis and psychotic symptoms. Psychopharmacology 65: 73-77.
2. SEGAL, D. S. & D. S. JANOWSKY. 1978. Psychostimulant-induced behavioral effects: possible models of schizophrenia. In Psychopharmacology: a Generation of Progress. M. A. Lipton, A. DiMascio & K. F. Killam, Eds. 1113-1123. Raven Press. New York.
3. SATO, M., C-C. CIIEN, K. AKIYAMA & S. OTSUKI. 1983. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol. Psychiatry 18: 429-440.
4. ANGRIST, B. 1994. Amphetamine psychosis: clinical variations of the syndrome. In Amphetamine and Its Analogs. D. S. Segal, Ed. 387-414. Academic Press. New York.
5. UTENA, H. 1966. Behavioral aberrations in methamphetamine-intoxicated animals and chemical correlates in the brain. Prog. Brain Res. 21B: 192-207.
6. HOROWITZ, M. J. 1969. Flashbacks: recurrent intrusive images after the use of LSD. Am. J. Psychiatry 126: 565-569.
7. MATEFY, R. E., C. HAYES & J. HIRSCH. 1978. Psychedelic drug flashbacks: subjective reports and biographical data. Addict. Behav. 3: 165-178.
8. ANISMAN, H. & L. S. SKLAR. 1979. Catecholamine depletion in mice upon reexposure to stress: modification of the escape deficits produced by inescapable shock. J. Comp. Physiol. Psychol. 93: 610-625.
9. CASSENS, G., M. ROFFMAN, A. KURUC, P. J. ORSULAK & J. J. SCHILDKRAUT. 1980. Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock. Science 209: 1138-1139.
10. MIYAZAKI, T., T. KOJOMA, M. YASHIKI, H. WAKAMOTO, Y. IWASAKI & T. TANIGUCHI. 1993. Site dependence of methamphetamine concentrations in blood samples collected from cadavers of people who had been methamphetamine abusers. Am. J. Forensic Med. Pathol. 14: 121-124.
11. MIWA, S., M. FUJIWARA, M. INOUE & M. FUJIWARA. 1986. Effects of hypoxia on the activities of noradrenergic and dopaminergic neurons in the rats. J. Neurochem. 47: 63-69.
12. SPIELBERGER, C. D. 1983. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press. Palo Alto, CA.
13. DIMSDALE, J. E. & J. MOSS. 1980. Plasma catecholamines in stress and exercise. JAMA 243: 340-342.
14. OVERALL, J. E. & D. R. GORHAM. 1962. The brief psychiatric rating scale. Psychol. Rep. 10: 799-812.
15. HOLSTEN, F. 1976. Flashbacks: a personal follow-up. Arch. Psychiatr. Nervenkr. 222: 293-304.
16. CHARNEY, D. S., A. Y. DEUTCH, J. H. KRYSTAL, S. M. SOUTHWICK & M. DAVIS. 1993. Psychobiological mechanisms of posttraumatic stress disorder. Arch. Gen. Psychiatry 50: 294-305.
17. ZIEGLER, M. G., C. R. LAKE, J. H. WOOD, B. R. BROOKS & M. H. EBERT. 1977. Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood-cerebrospinal fluid barrier for norepinephrine. J. Neurochem. 28: 677-679.
18. KOPIN, I. J., E. K. GORDON, D. C. JIMERSON & R. J. POLINSKY. 1983. Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 219: 73-75.
19. MAAS, J. W., S. A. CONTRERAS, E. SELESHI & C. L. BOWDEN. 1988. Dopamine metabolism and disposition in schizophrenic patients: studies using debrisoquin. Arch. Gen. Psychiatry 45: 553-559.
20. VAN KAMMEN, D. P., J. P. DOCHERTY & W. E. BUNNEY. 1982. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol. Psychiatry 17: 233-242.
21. PICKAR, D., A. BREIER, J. K. HSIAO, A. R. DORAN, O. M. WOLKOWITZ, C. N. PATO, P. E. KONICKI & W. Z. POTTER. 1990. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis: implications for regional brain dysfunction in schizophrenia. Arch. Gen. Psychiatry 47: 641-648.
22. GLOWINSKI, J., D. HERVÉ & J. P. TASSIN. 1988. Heterologous regulation of receptors on target cells of dopamine neurons in the prefrontal cortex, nucleus accumbens, and striatum. Ann. N. Y. Acad. Sci. 537: 112-123.
23. VAN KAMMEN, D. P., J. PETTERS, J. YAO, W. B. VAN KAMMEN, T. NEYLAN, D. SHAW & M. LINNOILA. 1990. Norepinephrine in acute exacerbations of chronic schizophrenia: negative symptoms revised. Arch. Gen. Psychiatry 47: 161-168.
24. LEWIS, D. A., M. J. CAMBELL, S. L. FOOTE, M. GOLDSTEIN & J. H. MORRISON. 1987. The distribution of tyrosine hydroxylase-immunoreactive fibers in primate neocortex is widespread but regionally specific. J. Neurosci. 7: 279-290.
25. MAJOR, L. F., P. LERNER, F. K. GOODWIN, J. C. BALLENGER, G. L. BROWN & W. LOVENBERG. 1980. Dopamine β-hydroxyIase in CSF: relationship to personality measures. Arch. Gen. Psychiatry 37: 308-310.
26. STERNBERG, D. E., D. P. VAN KAMMEN, P. LERNER, J. C. BALLENGER, S. R. MARDER, R. M. POST & W. E. BUNNEY. 1983. CSF dopamine β-hydroxylase in schizophrenia: low activity associated with good prognosis and good response to neuroleptic treatment. Arch. Gen. Psychiatry 40: 743-747.
27. MARKIANOS, E. S., I. NYSTRÖM, H. REICHEL & N. MATSUSSEK. 1976. Serum dopamine-β-hydroxylase in patients and normals: effects of d-amphetamine and haloperidol Psychopharmacology 50: 259-267.
28. WODE-HELGODT, B., B. FYRÖ, B. GULLBERG & G. SEDVALL. 1977. Effects of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatr. Scand. 56: 129-142.
29. HÄRNRYD, C., L. BJERKENSTEDT, B. GULLBERG, G. OXENSTIERNA, G. SEDVALL & F. A. WIESEL. 1985. Time course for effects of sulphide and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr. Scand. Suppl. 321: 75-92.
30. DINAN, T. G. & G. ASTON-JONES. 1985. Chronic haloperidol inactivates brain noradrenergic neurons. Brain Res. 325: 385-388.
31. ANDÉN, N.B., S. G. BUTCHER, H. CORRODI, K. FUXE & U. UNGERSTEDT. 1970. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur. J. Pharmacol. 11: 303-314.
32. BOWERS, M. B. 1975. Thioridazine: central dopamine turnover and clinical effects of antipsychotic drugs. Clin. Pharmacol. Ther. 17: 73-78.
33. GATTAZ, W. F., P. RIEDERER, G. P. REYNOLDS, D. GATTAZ & H. BECKMANN. 1983. Dopamine and noradrenaline in the cerebrospinal fluid of schizophrenic patients. Psychiatr. Res. 8: 243-250.
34. CASTELLANI, S., M. G. ZIEGLER, D. P. VAN KAMMEN, P. E. ALEXANDER, S. G. SIRIS & C. R. LAKE. 1982. Plasma norepinephrine and dopamine-β-hydroxylase activity in schizophrenia. Arch. Gen. Psychiatry 39: 1145-1149.
35. KEMALI, D., M. D. VECCHIO & M. MAJ. 1982. Increased noradrenaline levels in CSF and plasma of schizophrenic patients. Biol. Psychiatry 17: 711-717.
36. LAKE, C. R., D. E. STERNBERG, D. P. VAN KAMMEN, J. C. BALLENGER, M. G. ZIEGLER, R. M. POST, I. J. KOPIN & W. E. BUNNEY. 1980. Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science 207: 331-333.
37. VAN KAMMEN, D. P., H. ÅGREN, J. K. JAO, D. T. O'CONNOR, J. GURKLIS & J. L. PETERS. 1994. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am. J. Psychiatry 151: 379-384.
38. BERNALD, P. & S. TROUVÉ. 1976. Sémilogie Psychiatrique. 206-220. Massen et Cie. Paris.
39. GELDER, M., D. GATH & R. MAYOU. 1989. Signs and symptoms of mental disorder. In Oxford Textbook of Psychiatry. 2nd edit. 1-36. Oxford University Press. Oxford, New York, Melbourne.